HR 9661
  • Introduced
    Jul 14, 2026
  • Passed House
  • Passed Senate
  • Became Law
HR 9661
United States House Bill
Did you know we offer free bill tracking in Congress and 50 states, AI tools to streamline your work, and a great mobile app? Sign up here
To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Last Action See all actions
House • Jul 14, 2026: Referred to the House Committee on Energy and Commerce.

Summary

Comments on HR 9661

Tweets

Whip Lists

Sponsors
Votes
Looks like there aren't any voting records available at this moment.
Actions
  • Jul 14, 2026 | House
    • Introduced in House
    • Referred to the House Committee on Energy and Commerce.
Bill Texts
Looks like there aren't any bill texts available at this moment.
Documents
Looks like we don't have any documents available at this moment.
Sources